Skip to main content

Table 2 Neonatal comorbidities of the levothyroxine nontreatment and treatment groups

From: Thyroid dysfunction in preterm infants born before 32 gestational weeks

  Nontreatment
N = 145
Treatment
N = 35
p Adjusted p*
Intraventricular hemorrhage (≥grade III) (%) 7 (4.8) 5 (14.3) 0.059
Symptomatic patent ductus arteriosus (%) 81 (55.9) 24 (68.6) 0.187
Necrotizing enterocolitis (≥stage II) (%) 13 (9.0) 3 (8.6) 1.000
Late-onset sepsis (%) 12 (8.3) 6 (17.1) 0.124
Bronchopulmonary dysplasia (%) 73 (50.3) 19 (54.3) 0.710
LASER therapy for retinopathy of prematurity (%) 39 (26.9) 11 (31.4) 0.675
Periventricular leukomalacia (%) 14 (9.7) 8 (22.9) 0.044 0.015
  1. Values are presented as numbers (%)
  2. *Adjusted for variables including gestational age and birth weight percentile used as categorical variables (23–25 weeks, 26–28 weeks, 29–31 weeks for gestational age; < 33%, 33–67, > 67% for birth weight percentile), cesarean section, maternal pregnancy-induced hypertension and periventricular leukomalacia